Oncology Pre-ESMO insights: Corcept on platinum-resistant ovarian can... pharmaphorum speaks with Corcept Therapeutics about its presentation of data in platinum-resistant ovarian cancer at both ASCO and ahead of ESMO 2025.
Oncology Advancing the frontiers of cancer diagnostics: Post-ASCO wit... Post-ASCO 2025, Eric Matthews, chief business officer at Caris Life Sciences, discusses advancing the frontier of cancer diagnostics and treatment.
Oncology Putting patients and their families first: Dr Corina Dutcus,... Dr Corina Dutcus, senior vice president and oncology global clinical development lead at Eisai, discusses the data Eisai presented at ASCO 2025.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.